CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Skye Bioscience Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Skye Bioscience Inc
11250 EL CAMINO REAL, SUITE 100
Phone: (858) 410-0266p:858 410-0266 SAN DIEGO, CA  92130  United States Ticker: SKYESKYE
Business Summary
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Paul A.Grayson 60 10/25/2024 8/18/2023
Chief Executive Officer, Director Punit S.Dhillon 43 10/25/2024 12/31/2017
Chief Financial Officer KaitlynArsenault 37 10/4/2021 10/4/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Emerald Health Therapeutics Inc 210 - 800 West Pender Street VANCOUVER BC Canada
Bird Rock Bio, Inc. 505 Coast Blvd S La Jolla CA United States

Business Names
Business Name
Bird Rock Bio Sub, Inc.
Bird Rock Bio, Inc.
EMBI
9 additional Business Names available in full report.

General Information
Number of Employees: 11 (As of 12/31/2023)
Outstanding Shares: 30,974,559 (As of 12/31/2024)
Shareholders: 190
Stock Exchange: NASD
Federal Tax Id: 271679428
Fax Number: (775) 782-2611


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 19, 2025